- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07683793
A Study to Compare How CHF10196 (Florensocatib) is Absorbed Into the Blood When Given Alone and With a Drug That Reduces Stomach Acid in Healthy Male Participants
An Open-label, Fixed-sequence, Non-randomised, Drug-drug Interaction Study to Evaluate the Effect of Pantoprazole (Proton Pump Inhibitor) on the Pharmacokinetics of CHF10196 in Healthy Male Participants.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 1
Contactos e Locais
Contato de estudo
- Nome: Chiesi Clinical trial Info
- Número de telefone: +390521279715
- E-mail: clinicaltrials_info@chiesi.com
Locais de estudo
-
-
-
Leeds, Reino Unido
- Fortrea Clinical Research Unit (CRU) Limited
-
Contato:
- Firas Almezedi
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
Aceita Voluntários Saudáveis
Descrição
Key Inclusion Criteria:
- BMI (body mass index) between 18.0 and 30.0 kg/m²
- Weight between 45 and 100 kg
- Non-smokers or ex-smokers (<5 pack-years)
- Clinically healthy based on medical history and examination
- Normal vital signs
- Normal ECG
- Willingness to comply with contraception requirements
Key Exclusion Criteria:
- Recent participation in another clinical study
- Significant medical conditions
- Abnormal laboratory values
- Positive HIV or hepatitis tests
- Recent infection or COVID-19
- Drug or alcohol abuse
- Use of prohibited medications
- Gastrointestinal surgery affecting absorption
- Hypersensitivity to study drugs
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Fixed Sequence Treatment
CHF10196 - Pantoprazole - Pantoprazole with CHF10196
|
Treatment Period 1: CHF10196 single dose administration on Day1; Treatment Period 2: CHF10196 single dose administration after pantoprazole single dose administration on Day13 Treatment Period 2: Pantoprazole single dose administration from Day8 to Day13 |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
PK parameter: AUC0-∞
Prazo: pre-dose up to 168 hours post-dose
|
comparing the ratio of adjusted geometric means for area under the concentration time curve from time 0 extrapolated to infinity (AUC0-∞) when CHF10196 administered alone and when administered with pantoprazole
|
pre-dose up to 168 hours post-dose
|
|
PK parameter: AUC0-t
Prazo: pre-dose up to 168 hours post-dose
|
comparing the ratio of adjusted geometric means for area under the plasma concentration time curve from time 0 to last quantifiable concentration (AUC0-t) when CHF10196 administered alone and when administered with pantoprazole
|
pre-dose up to 168 hours post-dose
|
|
PK parameter: Cmax
Prazo: pre-dose up to 168 hours post-dose
|
comparing the ratio of adjusted geometric means for maximum observed concentration when CHF10196 administered alone and when administered with pantoprazole
|
pre-dose up to 168 hours post-dose
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Safety and tolerability: Incidence of adverse events (AE)
Prazo: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
Number and percentage of adverse events (AE) when CHF10196 administered alone and when administered with pantoprazole
|
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
|
Safety and tolerability: Change from baselines for vital signs: PR
Prazo: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
Mean changes from baselines to each post-dose timepoint in PR (pulse rate), by treatment period (TP). Baselines (the last value before the first administration of any CHF10196 of each TP or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196) |
Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
|
Safety and tolerability: Change from baselines for vital signs - RR
Prazo: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
Mean changes from baselines to each post-dose timepoint in vital signs: RR (respiratory rate) by treatment period (TP). Baselines (the last value before the first administration of any CHF10196 of each TP or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196) |
Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
|
Safety and tolerability: Change from baselines for vital signs - blood pressure
Prazo: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
Mean changes from baselines to each post-dose timepoint in vital signs (Systolic Blood Pressure and Diastolic Blood Pressure) by treatment period (TP). Baselines (the last value before the first administration of any CHF10196 of each TP or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196) |
Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
|
Safety and tolerability: Change from baselines for ECG
Prazo: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
change from baselines in milliseconds (ms). Intervals recorded: PR , RR, QT, QTc, QRS duration, QTcF (Fridericia-corrected QT interval Baselines (the last value before the first administration of any CHF10196 of each treatment period (TP) or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196 |
Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
|
Safety and tolerability: Change from baseline for ECG (HR)
Prazo: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
change from baseline for ECG recording of heart rate (HR) Baselines (the last value before the first administration of any CHF10196 of each Treatment Period (TP) or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196). |
Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
|
Safety and tolerability: Change from baseline for laboratory abnormalities
Prazo: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
Number of participants with abnormal blood laboratory test results.
Quantitative laboratory parameters (chemistry and haematology) will be summarised by treatment as absolute value and change from baseline using descriptive statistics
|
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
|
Additional pharmacokinetic parameters: AUC0-24h
Prazo: From Day 1 to Day 2 for treatment period 1; from Day 13 to Day 14 for treatment period 2
|
comparing the ratio of adjusted geometric means for the area under the plasma concentration time curve from time 0 to 24 h post-dose when CHF10196 administered alone and when administered with pantoprazole (with their 90% two-sided Confidence Intervals)
|
From Day 1 to Day 2 for treatment period 1; from Day 13 to Day 14 for treatment period 2
|
|
Additional pharmacokinetic parameters: CL/F
Prazo: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
comparing the total body clearance (CL/F) by treatment period using descriptive statistics
|
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
|
Additional pharmacokinetic parameters: t1/2
Prazo: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
comparing the terminal half-life (t1/2) by treatment period using descriptive statistics
|
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
|
Additional pharmacokinetic parameters: Vd/F
Prazo: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
comparing the apparent volume of distribution (Vd/F) by treatment period using descriptive statistics
|
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
|
Additional pharmacokinetic parameters: tmax
Prazo: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
Evaluating the Hodges-Lehmann non-parametric estimate of location shift between CHF10196 with pantoprazole (test) and CHF10196 alone (reference) in median time corresponding to maximum plasma when CHF10196 administered alone and when administered with pantoprazole concentration (tmax)
|
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Benjamen Monaghan, Fortrea Clinical Research Unit (CRU)
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CLI-10196AA1-05
- 1014440 (Outro identificador: IRAS)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .